WOA advances its lower-cost lupin manufacturing transition

German manufacturing exit reaches its critical phase

Wide Open Agriculture Ltd (ASX:WOA) has moved from strategy to execution on its attempt to rebuild the economics of its lupin ingredients business. Production at the German facility has stopped, the lease has been exited, surplus plant and equipment has been sold, and the local subsidiary is being wound up.

WOA said equipment-sale proceeds are expected to more than offset the remaining wind-down costs, with any residual capital to be returned to the group once the process is complete. Fixed operating costs are expected to fall further through December 2026, while the overall wind-down is targeted for completion by mid-2027. The facility had demonstrated commercial-scale production and helped secure regulatory approvals, including China market access, but WOA said its size, European energy costs and lack of integrated whole-of-seed processing made it unsuitable for the intended long-term model.

Four Asian partners enter technical assessment

The more consequential test is whether WOA can replace owned manufacturing with a reliable, lower-cost supply chain. The company signed four non-binding framework agreements with prospective manufacturers in India, Vietnam and Indonesia during the quarter, building on the four-partner manufacturing shortlist previously assembled for the transition.

The frameworks protect WOA's intellectual property and restrict each manufacturer from producing lupin-based products for itself or third parties during the agreement and for five years after termination. Detailed information on process steps, equipment, production parameters and specifications is now being exchanged, with laboratory and production trials, ramp-up timing and commercial terms still to be worked through. The agreements are not commercial commitments: WOA has not yet selected a preferred partner or signed a definitive manufacturing agreement.

Ingredient portfolio gains independent support

WOA is also trying to make more of each lupin seed. Independent testing found its Angusti lupin oil non-irritating, with no evidence of allergic contact dermatitis across 55 participants in a three-week Human Repeat Insult Patch Test. Trial sales have been secured, while prospective cosmetics and personal-care customers assess samples.

Separate CSIRO testing found WOA's lupin kernel fibre retained performance under heat and shear and had strong water-binding properties, characteristics relevant to food manufacturers. The company also disclosed in-vitro research on fermentation by gut bacteria, but noted that the fibre has not been tested in human clinical studies and that it is making no therapeutic or health claims.

A$311 million facility remains a long-term option

After the quarter, WOA completed an industrial-scale study for a proposed Western Australian facility producing 10,000 tonnes of lupin protein isolate a year, alongside up to 17,000 tonnes of fibre and 700 tonnes of oil. The study estimated capital costs of approximately A$311 million in Q4 2025 dollars, including a 15% contingency in the financial modelling, and modelled annual revenue of A$240 million to A$295 million at full nameplate capacity.

Those figures are indicative study outcomes, not forecasts. The project remains unfunded and has no investment decision, leaving contract manufacturing as the immediate commercial test. WOA said the engineering work may nevertheless help it assess partners, refine production economics and engage potential strategic partners and financiers. The scale of the proposal contrasts sharply with the company's near-term target of 500 to 1,000 tonnes per year through external manufacturers.

Cash position leaves little room for execution delays

WOA held A$1.098 million in cash at 30 September after using A$449,000 in operating activities during the quarter. It received A$337,000 from selling plant and equipment and made A$58,000 in lease-related principal repayments. On the quarter's reported operating cash usage, the Appendix 4C calculates 2.45 quarters of funding, before considering any future changes in spending.

The company expects a net R&D Tax Incentive rebate of A$1.2 million to A$1.5 million in the December quarter, subject to lodgement and Australian Taxation Office processing. That expected inflow is not yet cash in hand. The next hard markers are therefore operational: whether a preferred manufacturing partner emerges, whether trials produce specification-compliant protein, and when commercial supply can resume for existing customers, including the minimum 50-tonne purchase commitment linked to WOA's China distribution arrangements.